Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Grandfield & Dodd LLC

Grandfield & Dodd LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,821 shares of the company’s stock after acquiring an additional 280 shares during the period. Grandfield & Dodd LLC’s holdings in Neurocrine Biosciences were worth $1,823,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after purchasing an additional 90 shares during the period. Fifth Third Bancorp grew its position in Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after buying an additional 92 shares during the period. Total Clarity Wealth Management Inc. grew its position in Neurocrine Biosciences by 4.3% during the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock worth $335,000 after buying an additional 100 shares during the period. Commerce Bank increased its holdings in Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after buying an additional 108 shares in the last quarter. Finally, Caprock Group LLC lifted its position in shares of Neurocrine Biosciences by 7.0% during the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock valued at $230,000 after acquiring an additional 109 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $119.13 on Wednesday. The company has a market cap of $12.06 billion, a P/E ratio of 31.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $108.14 and a 12 month high of $157.98. The company has a 50-day moving average of $118.44 and a 200-day moving average of $132.40.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NBIX. Robert W. Baird upped their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Guggenheim lifted their price target on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $131.00 to $159.00 in a research note on Thursday, August 29th. Finally, Citigroup lifted their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.